The Life Raft Group had the pleasure of hosting the global New Horizons GIST meeting this year in our Wayne, New Jersey office. This international meeting traditionally gathers global GIST advocates with the shared [...]
The fourteenth annual “Night to Fight Cancer” to benefiting the Life Raft Group’s research programs took place on October 19, 2017 at Midtown Loft and Terrace in New York City. This year Jerry Cudzil, [...]
The Life Raft Group and UCSD hosted a three-day event at University of California, San Diego UCSD-Moores Cancer Center from July 13th through July 15th. A GIST Awareness Day (GAD) event took place on July [...]
Drs. Breelyn Wilky, Jonathan Trent, AlanLivingstone, and Pablo Bejarano show off theirrare in Miami. The 2015 GIST Days of Learning Tour continues to be successful. A GIST Day of Learning (GDOL) is [...]
GIST advocates from around the world gathered in Miami for the annual New Horizons conference. This international meeting was launched by Novartis Oncology in 2003 with the title, “New Horizons in Treating CML and [...]
On the evening of Tuesday, April 14, the Lurie Cancer Center of Northwestern University Medical Center in Chicago, Illinois played host to the second stop in the nationwide GIST Day of Learning (GDOL) tour [...]
Sutent 37.5 mg Ease of use and lower costs may be on the horizon for Sutent patients who are currently on a 37.5 milligram prescription. Available now, Pfizer has released a new [...]
The Food and Drug Administration, in a much-anticipated announcement for Gastrointestinal Stromal Tumor patients, approved Bayer Pharmaceutical’s drug, Stivarga, for use as a third-line treatment for advanced GIST in February.
Pfizer Pharmaceuticals is offering Sutent in Touch, a program to support GIST patients on its drug Sutent. The program is free and patients can sign up by calling (1-877-578-8368). Sutent in Touch links patients to Oncology [...]
A new phase I/II clinical trial will soon be opening for pediatric and young adults with GIST. This trial will be testing Sutent (sunitinib), the currently approved second-line treatment for GIST, in young patients. At the current time, the optimal dose for Sutent is not known for pediatric patients. This trial will help assess the safety and tolerability of Sutent in young patients.